Table 3.

Risks for all‐cause mortality and MACE according to different ARBs compared to those associated with losartan

	Crude model				Adjusted model
	HR	95% CI		p value	HR	95% CI		p value
		Low	High			Low	High
All‐cause mortality (ref. = losartan)
Candesartan	0.901	0.856	0.948	0.003	0.994	0.943	1.046	0.613
Fimasartan	0.701	0.639	0.769	<0.001	0.975	0.889	1.070	0.858
Irbesartan	0.905	0.850	0.964	0.009	0.947	0.889	1.008	0.180
Olmesartan	0.813	0.778	0.849	0.065	1.004	0.961	1.049	0.256
Telmisartan	0.771	0.740	0.802	<0.001	0.965	0.927	1.005	0.331
Valsartan	0.838	0.807	0.870	0.781	0.993	0.956	1.031	0.538
MACE (ref. = losartan)
Candesartan	1.039	1.002	1.078	<0.001	1.066	1.028	1.106	0.015
Fimasartan	0.810	0.759	0.864	<0.001	1.001	0.938	1.069	0.400
Irbesartan	1.098	1.051	1.146	<0.001	1.079	1.033	1.127	0.007
Olmesartan	0.901	0.873	0.930	0.001	1.017	0.986	1.050	0.567
Telmisartan	0.864	0.839	0.890	<0.001	0.995	0.966	1.024	0.019
Valsartan	0.932	0.907	0.958	0.262	1.022	0.994	1.050	0.771

Note: The following variables were controlled in the adjusted model: age, sex, body mass index, systolic blood pressure, diabetes mellitus, dyslipidemia, cigarette smoking, alcohol drinking, physical activity, household income, glomerular filtration rate, and the use of calcium channel blockers, beta‐blockers, angiotensin‐converting enzyme inhibitors, diuretics, antithrombotics, and statins.

Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event.